title: 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.
abstract: BACKGROUND
  The aim of this study was to investigate whether 14-3-3η, a specific isoform of a family of proteins regulating processes such as cellular signalling, activates cell-signalling pathways and induces factors known to contribute to the pathophysiology of rheumatoid arthritis (RA). We also investigated whether 14-3-3η is associated with more severe disease in both early and established RA.
  
  
  METHODS
  We investigated the effect of 14-3-3η on the activation of RA-relevant signalling cascades and induction of proinflammatory mediators that contribute to the joint damage process. 14-3-3η titres from 33 patients with early RA (mean RA duration = 1.8 months) and from 40 patients with established RA were measured in serum drawn at the 3-year time point of the Behandel Strategieën study. The relationship between 14-3-3η titres and standard clinical variables was investigated by correlation analysis. The association with radiographic damage and radiographic progression over at least a 2-year period was investigated using univariate and multivariate regression analyses.
  
  
  RESULTS
  14-3-3η activated selected members of the mitogen-activated protein kinase (MAPK) family, mainly extracellular regulated kinase 1/2 and c-Jun kinase, but not p38MAPK. Activation by 14-3-3η, using levels spanning the concentration range found in RA patient serum, resulted in the induction of inflammatory transcripts such as interleukin 1 (IL-1) and IL-6 and factors linked to the joint damage process, such as receptor activator of nuclear factor κB ligand and matrix metalloproteinase 1. Serum 14-3-3η correlated significantly with rheumatoid factor (RF) (r = 0.43) and anticitrullinated protein antibodies (ACPAs) (r = 0.31) in the early RA cohort, but not with C-reactive protein (CRP) or the Disease Activity Score in 28 joints in either cohort. Serum 14-3-3η concentrations were significantly higher in patients with radiographically assessed joint damage and in those who had radiographic progression. By multivariate analysis, we show that 14-3-3η complemented markers such as CRP, RF and ACPA in informing RA radiographic status and/or progression.
  
  
  CONCLUSIONS
  Extracellular 14-3-3η activates key signalling cascades and induces factors associated with the pathogenesis of RA at concentrations found in patients with RA, and its expression is higher in patients with radiographic damage and RA progression.
authors.forename: Walter P
authors.initials: WP
authors.lastname: Maksymowych
authors.forename: Désirée
authors.initials: D
authors.lastname: van der Heijde
authors.forename: Cornelia F
authors.initials: CF
authors.lastname: Allaart
authors.forename: Robert
authors.initials: R
authors.lastname: Landewé
authors.forename: Gilles
authors.initials: G
authors.lastname: Boire
authors.forename: Paul P
authors.initials: PP
authors.lastname: Tak
authors.forename: Yuan
authors.initials: Y
authors.lastname: Gui
authors.forename: Aziz
authors.initials: A
authors.lastname: Ghahary
authors.forename: Ruhangiz
authors.initials: R
authors.lastname: Kilani
authors.forename: Anthony
authors.initials: A
authors.lastname: Marotta
mesh_terms: D048948:14-3-3 Proteins / Q000097:blood*; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000000981:diagnostic imaging / Q000473:pathology*; D015415:Biomarkers / Q000097:blood*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007596:Joints / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011859:Radiography
chemical_list: D048948:14-3-3 Proteins; D015415:Biomarkers; C482984:YWHAH protein, human
references.citation: Int Immunopharmacol. 2008 May;8(5):679-87
references.pmid: 18387510
references.citation: J Biol Chem. 2005 Jun 17;280(24):23349-55
references.pmid: 15826944
references.citation: J Leukoc Biol. 1994 Jul;56(1):27-35
references.pmid: 8027667
references.citation: BMC Cancer. 2011 Sep 20;11:397
references.pmid: 21933426
references.citation: Orthod Craniofac Res. 2009 Aug;12(3):178-86
references.pmid: 19627519
references.citation: J Rheumatol. 2009 Aug;36(8):1785-91
references.pmid: 19671813
references.citation: Mult Scler. 2004 Oct;10(5):477-81
references.pmid: 15471360
references.citation: J Neurol Sci. 2007 Sep 15;260(1-2):159-66
references.pmid: 17561120
references.citation: Arthritis Res Ther. 2013 Aug 14;15(4):R86
references.pmid: 23945134
references.citation: Age Ageing. 2008 Jul;37(4):467-9
references.pmid: 18460497
references.citation: Arthritis Rheum. 2005 Nov;52(11):3381-90
references.pmid: 16258899
references.citation: Rheumatology (Oxford). 2009 Jan;48(1):45-8
references.pmid: 19056796
references.citation: Arthritis Rheum. 2004 Jun 15;51(3):488-97
references.pmid: 15188338
references.citation: Arthritis Rheum. 2011 Oct;63(10):2865-72
references.pmid: 21647867
references.citation: J Biol Chem. 2009 Jan 16;284(3):1853-62
references.pmid: 19028685
references.citation: Rheumatology (Oxford). 2011 Jan;50(1):93-100
references.pmid: 20639266
references.citation: FEBS Lett. 2002 Feb 20;513(1):53-7
references.pmid: 11911880
references.citation: Asian Pac J Cancer Prev. 2012;13(4):1253-9
references.pmid: 22799314
references.citation: Arthritis Rheum. 1997 Feb;40(2):217-25
references.pmid: 9041933
references.citation: J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8
references.pmid: 16046478
references.citation: Histopathology. 2011 Apr;58(5):705-11
references.pmid: 21401702
references.citation: Ann Rheum Dis. 2012 Mar;71(3):415-23
references.pmid: 21953337
references.citation: J Endocrinol. 2009 Sep;202(3):327-36
references.pmid: 19366886
references.citation: J Cell Physiol. 2009 Oct;221(1):221-31
references.pmid: 19530224
references.citation: J Rheumatol. 2007 Aug;34(8):1650-7
references.pmid: 17611984
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):229-36
references.pmid: 22315133
references.citation: Sex Transm Infect. 2000 Oct;76(5):408
references.pmid: 11141866
references.citation: Arthritis Rheum. 2008 May;58(5):1293-8
references.pmid: 18438829
references.citation: J Cell Sci. 2004 Apr 15;117(Pt 10):1875-84
references.pmid: 15090593
references.citation: J Appl Physiol (1985). 2011 Dec;111(6):1575-83
references.pmid: 21757573
references.citation: Trends Immunol. 2011 Feb;32(2):89-95
references.pmid: 21145789
references.citation: Drug Des Devel Ther. 2012;6:245-50
references.pmid: 23055694
references.citation: Arthritis Res Ther. 2005;7(3):R592-603
references.pmid: 15899046
references.citation: BMC Neurol. 2006 Sep 21;6:35
references.pmid: 16989662